Lumida
/ARWR
⌘K
Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

ARWR
$82.85USD↑+0.11%+0.09 today

MARKET CAP

11.7B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$82 – $86

52W RANGE

$28
$95

AI Summary

Stalk
StalkMedium

ARWR has delivered a clear momentum breakout above the ~77 resistance on heavy volume, signaling a new expansionary phase, but price is currently stretched above rising EMAs and in extreme overbought territory. Medium-term bias remains bullish in Stage 2 with HH/HL structure intact. Execution is best deferred until a pullback into the 77–79 support zone near the 9/20 EMAs for better risk–reward.

  • ↑Phase 3 plozasiran cut triglycerides 79–81% and reduced pancreatitis by 78%.
  • ↑Q3 revenue reached $75M vs. $28M YoY; Redempla prescriptions doubled.
  • ↓Q3 net loss widened to $194.3M vs. $175.2M YoY; opex $245M.
Full analysis →
Insider Trades39 trades
Date↓SideTicker↕Insider↕Role↕Shares↕Price↕Mkt Cap↕52W High↕52W Low↕Value↕% Chg↕Rule↕AI View↕
Apr 23, 2026SellARWRJames C HamiltonChief Medical Officer10,000$75.00$11.7B-13.24%+196.53%$750.0K-4.22%10b5-1Stalk
Apr 22, 2026SellARWRDaniel Joseph ApelChief Financial Officer13,095$71.35$11.7B-13.24%+196.53%$934.3K-2.52%10b5-1Stalk
Mar 5, 2026SellARWRJames C HamiltonChief Medical Officer10,000$64.19$11.7B-13.24%+196.53%$641.9K-4.05%10b5-1Stalk
Jan 6, 2026SellARWRPatrick O'BrienCOO2,500$70.81$11.7B-13.24%+196.53%$177.0K-0.11%—Stalk
Jan 5, 2026SellARWRJames C HamiltonChief Medical Officer40,164$63.11$11.7B-13.24%+196.53%$2.5M-3.03%10b5-1Stalk
Jan 2, 2026SellARWRChristopher Richard AnzaloneChief Executive Officer13,187$66.10$11.7B-13.24%+196.53%$871.7K-0.17%10b5-1Stalk
Dec 31, 2025SellARWRPatrick O'BrienCOO52,293$59.73$11.7B-13.24%+196.53%$3.1M-0.61%10b5-1Stalk
Dec 29, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer103,452$37.64$11.7B-13.24%+196.53%$3.9M+0.00%10b5-1Stalk
Dec 19, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer26,031$68.04$11.7B-13.24%+196.53%$1.8M-0.14%—Stalk
Dec 17, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer85,000$64.04$11.7B-13.24%+196.53%$5.4M-0.55%—Stalk
Dec 15, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer184,298$67.00$11.7B-13.24%+196.53%$12.3M-0.39%—Stalk
Oct 1, 2025SellARWRJames C HamiltonChief Medical Officer20,000$35.00$11.7B-13.24%+196.53%$700.0K-8.62%10b5-1Stalk
Sep 12, 2025SellARWRJames C HamiltonChief Medical Officer15,000$30.00$11.7B-13.24%+196.53%$450.0K-6.07%10b5-1Stalk
Sep 2, 2025SellARWRJames C HamiltonChief Medical Officer15,000$25.00$11.7B-13.24%+196.53%$375.0K-5.72%10b5-1Stalk
Aug 13, 2025SellARWRJames C HamiltonChief Medical Officer10,000$20.00$11.7B-13.24%+196.53%$200.0K-1.84%10b5-1Stalk
Apr 9, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer141,122$10.87$11.7B-13.24%+196.53%$1.5M-0.70%—Stalk
Mar 13, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer51,425$15.07$11.7B-13.24%+196.53%$775.0K-1.25%—Stalk
Mar 3, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer600,000$12.67$11.7B-13.24%+196.53%$7.6M+0.00%10b5-1Stalk
Feb 7, 2025BuyARWRChristopher Richard AnzaloneChief Executive Officer9,550$20.10$11.7B-13.24%+196.53%$192.0K+0.25%—Stalk
Jan 6, 2025SellARWRJames C HamiltonChief Discovery/Trans Medicine32,729$19.82$11.7B-13.24%+196.53%$648.8K-5.57%10b5-1Stalk
Jan 6, 2025SellARWRPatrick O'BrienCOO and General Counsel37,184$19.80$11.7B-13.24%+196.53%$736.1K-2.26%10b5-1Stalk
Jan 6, 2025SellARWRKenneth Allen MyszkowskiChief Financial Officer45,167$19.77$11.7B-13.24%+196.53%$893.1K-2.35%10b5-1Stalk
Jan 2, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer11,520$19.05$11.7B-13.24%+196.53%$219.5K-0.31%10b5-1Stalk
Dec 23, 2024SellARWRChristopher Richard AnzaloneChief Executive Officer12,563$19.59$11.7B-13.24%+196.53%$246.1K-0.33%10b5-1Stalk
Dec 18, 2024SellARWRChristopher Richard AnzaloneChief Executive Officer26,712$21.24$11.7B-13.24%+196.53%$567.5K-0.24%10b5-1Stalk
Jul 2, 2024SellARWRTracie OliverChief Commercial Officer9,394$25.28$11.7B-13.24%+196.53%$237.5K-6.88%10b5-1Stalk
Apr 1, 2024SellARWRJames C HamiltonChief Discovery/Trans Medicine6,000$28.03$11.7B-13.24%+196.53%$168.2K-2.85%—Stalk
Mar 6, 2024SellARWRKenneth Allen MyszkowskiChief Financial Officer40,000$35.19$11.7B-13.24%+196.53%$1.4M-9.08%—Stalk
Jan 31, 2024SellARWRChristopher Richard AnzaloneChief Executive Officer114,998$23.44$11.7B-13.24%+196.53%$2.7M+0.00%10b5-1Stalk
Jan 12, 2024SellARWRJames C HamiltonChief Discovery/Trans Medicine7,940$36.89$11.7B-13.24%+196.53%$292.9K-1.83%10b5-1Stalk
Jan 5, 2024SellARWRTracie OliverChief Commercial Officer74$33.89$11.7B-13.24%+196.53%$2.5K-0.05%10b5-1Stalk
Jan 5, 2024SellARWRMartin Javier SanChief Medical Officer8,303$35.26$11.7B-13.24%+196.53%$292.8K-1.35%10b5-1Stalk
Jan 5, 2024SellARWRKenneth Allen MyszkowskiChief Financial Officer16,104$35.27$11.7B-13.24%+196.53%$567.9K-1.18%10b5-1Stalk
Jan 3, 2024SellARWRPatrick O'BrienCOO and General Counsel33,190$34.36$11.7B-13.24%+196.53%$1.1M-0.95%10b5-1Stalk
Jan 2, 2024SellARWRChristopher Richard AnzaloneChief Executive Officer9,952$31.01$11.7B-13.24%+196.53%$308.6K-0.13%10b5-1Stalk
Dec 20, 2023SellARWRChristopher Richard AnzaloneChief Executive Officer12,000$28.54$11.7B-13.24%+196.53%$342.5K-0.32%10b5-1Stalk
Nov 20, 2023SellARWRMartin Javier SanChief Medical Officer19,700$28.80$11.7B-13.24%+196.53%$567.3K-6.83%—Stalk
Oct 25, 2023SellARWRChristopher Richard AnzaloneChief Executive Officer24,338$24.21$11.7B-13.24%+196.53%$589.2K-0.65%10b5-1Stalk
Sep 18, 2023SellARWRChristopher Richard AnzaloneChief Executive Officer115,510$16.44$11.7B-13.24%+196.53%$1.9M+0.00%10b5-1Stalk